Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer.
Biomarkers, Tumor
Breast Neoplasms
/ etiology
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Genes, BRCA1
Genes, BRCA2
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Prognosis
Proto-Oncogene Protein c-fli-1
/ genetics
Transcriptome
Tumor Microenvironment
FLI1
breast cancer
tumour immune microenvironment
tumour-infiltrating lymphocyte
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
20
08
2019
revised:
31
01
2020
accepted:
06
03
2020
pubmed:
7
4
2020
medline:
8
9
2021
entrez:
7
4
2020
Statut:
ppublish
Résumé
Breast cancer is the most common cancer and the leading cause of cancer death among women in the world. Tumour-infiltrating lymphocytes were defined as the white blood cells left in the vasculature and localized in tumours. Recently, tumour-infiltrating lymphocytes were found to be associated with good prognosis and response to immunotherapy in tumours. In this study, to examine the influence of FLI1 in immune system in breast cancer, we interrogated the relationship between the FLI1 expression levels with infiltration levels of 28 immune cell types. By splitting the breast cancer samples into high and low expression FLI1 subtypes, we found that the high expression FLI1 subtype was enriched in many immune cell types, and the up-regulated differentially expressed genes between them were enriched in immune system processes, immune-related KEGG pathways and biological processes. In addition, many important immune-related features were found to be positively correlated with the FLI1 expression level. Furthermore, we found that the FLI1 was correlated with the immune-related genes. Our findings may provide useful help for recognizing the relationship between tumour immune microenvironment and FLI1, and may unravel clinical outcomes and immunotherapy utility for FLI1 in breast cancer.
Identifiants
pubmed: 32249526
doi: 10.1111/jcmm.15205
pmc: PMC7214163
doi:
Substances chimiques
Biomarkers, Tumor
0
FLI1 protein, human
0
Proto-Oncogene Protein c-fli-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5501-5514Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Biochem J. 1984 Aug 15;222(1):169-76
pubmed: 6477507
Genomics. 2019 Jul;111(4):886-892
pubmed: 29842950
Sci Rep. 2015 Dec 09;5:16964
pubmed: 26648527
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
BMC Med. 2015 Aug 17;13:195
pubmed: 26278220
Nature. 2008 Jan 31;451(7178):591-5
pubmed: 18235503
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Leukemia. 2000 Mar;14(3):439-45
pubmed: 10720139
Mol Biosyst. 2015 Oct;11(10):2620-34
pubmed: 26099739
Med Chem. 2019;15(5):496-509
pubmed: 30556503
J Theor Biol. 2015 Jan 7;364:284-94
pubmed: 25264267
J Theor Biol. 2018 Dec 7;458:92-102
pubmed: 30201434
PLoS One. 2015 Mar 30;10(3):e0121501
pubmed: 25821974
BMC Cancer. 2018 Mar 24;18(1):320
pubmed: 29573739
Curr Med Chem. 2004 Aug;11(16):2105-34
pubmed: 15279552
J Cell Biochem. 2003 Dec 15;90(6):1250-60
pubmed: 14635197
Nature. 2013 Jun 27;498(7455):521-5
pubmed: 23739335
J Theor Biol. 2011 Mar 21;273(1):236-47
pubmed: 21168420
J Cell Mol Med. 2020 May;24(10):5501-5514
pubmed: 32249526
Mol Ther Nucleic Acids. 2016;5:e332
pubmed: 28427142
Biochem J. 1983 Dec 1;215(3):465-9
pubmed: 6362659
Protein Sci. 1992 Mar;1(3):401-8
pubmed: 1304347
Bioinformatics. 2018 May 1;34(9):1448-1456
pubmed: 29106451
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Curr Gene Ther. 2018;18(5):257-267
pubmed: 30209997
Cancer Sci. 2007;98(11):1775-84
pubmed: 17727680
Curr Pharm Des. 2019;25(40):4223-4234
pubmed: 31782354
Biophys Chem. 1980 Dec;12(3-4):255-63
pubmed: 7225518
Development. 1999 Jun;126(14):3131-48
pubmed: 10375504
Neoplasia. 2014 Oct 23;16(10):801-13
pubmed: 25379017
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Genomics. 2020 Jan;112(1):276-285
pubmed: 30779939
Arch Immunol Ther Exp (Warsz). 2006 May-Jun;54(3):149-63
pubmed: 16652219
Oncol Lett. 2019 Feb;17(2):2177-2186
pubmed: 30675282
Mod Pathol. 2004 May;17(5):547-52
pubmed: 15001993
J Clin Pathol. 2007 Jun;60(6):694-700
pubmed: 16917000
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
J Theor Biol. 2019 Mar 21;465:1-6
pubmed: 30590059
Bioinformatics. 2005 Jan 1;21(1):10-9
pubmed: 15308540
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nature. 2016 May 02;533(7602):269-73
pubmed: 27135929
Oncotarget. 2016 Nov 8;7(45):74120-74131
pubmed: 27705919
Cancer. 2011 Jan 1;117(1):86-95
pubmed: 20737575
J Theor Biol. 2006 Jan 7;238(1):172-6
pubmed: 16043193
Biochem J. 1980 Jun 1;187(3):829-35
pubmed: 7188428
Cancer Med. 2016 Dec;5(12):3586-3587
pubmed: 27781408
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Genomics. 2020 Jan;112(1):859-866
pubmed: 31175975
Anal Biochem. 2008 Feb 15;373(2):386-8
pubmed: 17976365
Bioinformatics. 2019 Feb 1;35(3):398-406
pubmed: 30010789
Med Chem. 2015;11(3):218-34
pubmed: 25548930
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Brief Bioinform. 2019 Sep 27;20(5):1826-1835
pubmed: 29947743
J Proteome Res. 2019 Aug 2;18(8):3119-3132
pubmed: 31267738
Nucleic Acids Res. 2015 Jul 1;43(W1):W65-71
pubmed: 25958395
Bioinformatics. 2015 Nov 15;31(22):3666-72
pubmed: 26209429
Oncotarget. 2017 Apr 25;8(17):28169-28175
pubmed: 28423655
Med Chem. 2019;15(5):472-485
pubmed: 30569871
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Cancer Cell. 2013 Aug 12;24(2):229-41
pubmed: 23871637
J Proteome Res. 2002 Sep-Oct;1(5):429-33
pubmed: 12645914
Sci Rep. 2017 Feb 13;7:42362
pubmed: 28205576
Nature. 2011 Jul 24;476(7358):109-13
pubmed: 21785437
Mol Biosyst. 2017 Aug 22;13(9):1722-1727
pubmed: 28702580
Biochem J. 1983 Mar 1;209(3):573-80
pubmed: 6870784
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Bioinformatics. 2016 Feb 1;32(3):362-9
pubmed: 26476782
Science. 2016 Jul 8;353(6295):172-175
pubmed: 27338706
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Bioinformatics. 2018 Jan 1;34(1):33-40
pubmed: 28968797
Mol Immunol. 2015 Feb;63(2):566-73
pubmed: 25108845
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Anal Biochem. 2014 Jul 1;456:53-60
pubmed: 24732113
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Genomics. 2017 Oct 6;:
pubmed: 28989035
Bioinformatics. 2017 Jan 1;33(1):35-41
pubmed: 27531102
Biophys Chem. 1980 Dec;12(3-4):265-9
pubmed: 7225519
Oncotarget. 2015 Sep 15;6(27):23764-75
pubmed: 26156017
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Curr Top Med Chem. 2017;17(21):2337-2358
pubmed: 28413951
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Nat Rev Immunol. 2005 Aug;5(8):606-16
pubmed: 16056254
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Curr Top Med Chem. 2019;19(25):2283-2300
pubmed: 31648642
Anal Biochem. 2012 Jun 15;425(2):117-9
pubmed: 22459120
Open Biol. 2019 Jun 28;9(6):190054
pubmed: 31164042
Genomics. 2019 Dec;111(6):1274-1282
pubmed: 30179658
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Genomics. 2019 Aug 28;:
pubmed: 31472241
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
Int J Mol Sci. 2014 Feb 26;15(3):3495-506
pubmed: 24577312
Curr Med Chem. 2019 May 06;:
pubmed: 31060481
Curr Pharm Des. 2018;24(34):4013-4022
pubmed: 30451108
Nat Commun. 2013;4:2612
pubmed: 24113773
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1332-6
pubmed: 2304901
Proteins. 2001 May 15;43(3):246-55
pubmed: 11288174
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
Genomics. 2020 Mar;112(2):1500-1515
pubmed: 31472243
Bioinformatics. 2013 Apr 1;29(7):960-2
pubmed: 23426256
Mol Omics. 2018 Oct 8;14(5):341-351
pubmed: 30129640
PLoS One. 2011 Jan 19;6(1):e14556
pubmed: 21283518
Biophys Chem. 1988 May;30(1):3-48
pubmed: 3046672